Abstract
Summary
Arthritis Monoclonal Antibodies are a group of complex and effective biological agents used to treat arthritis and other immune-mediated inflammatory diseases
The global market for Arthritis Monoclonal Antibodies was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Arthritis Monoclonal Antibodies include AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis, Johnson & Johnson(Janssen), Pfizer Inc, Mylan, Genentech, GSK and AstraZeneca PLC, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Arthritis Monoclonal Antibodies, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Arthritis Monoclonal Antibodies by region & country, by Type, and by Application.
The Arthritis Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Arthritis Monoclonal Antibodies.
Market Segmentation
By Company
AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC
Segment by Type:
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Segment by Application
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Arthritis Monoclonal Antibodies manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Arthritis Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Arthritis Monoclonal Antibodies in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Arthritis Monoclonal Antibodies was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Arthritis Monoclonal Antibodies was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Arthritis Monoclonal Antibodies include AbbVie Inc, F. Hoffmann-La Roche Ltd, Novartis, Johnson & Johnson(Janssen), Pfizer Inc, Mylan, Genentech, GSK and AstraZeneca PLC, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Arthritis Monoclonal Antibodies, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Arthritis Monoclonal Antibodies by region & country, by Type, and by Application.
The Arthritis Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Arthritis Monoclonal Antibodies.
Market Segmentation
By Company
AbbVie Inc
F. Hoffmann-La Roche Ltd
Novartis
Johnson & Johnson(Janssen)
Pfizer Inc
Mylan
Genentech
GSK
AstraZeneca PLC
Segment by Type:
Remicade
Humira
Enbrel
Rituxan
Orencia
Actemra
Simponi
Cimzia
Segment by Application
Rheumatoid Arthritis
Osteoarthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Fibromyalgia
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Arthritis Monoclonal Antibodies manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Arthritis Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Arthritis Monoclonal Antibodies in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 Arthritis Monoclonal Antibodies Product Introduction
1.2 Global Arthritis Monoclonal Antibodies Market Size Forecast
1.3 Arthritis Monoclonal Antibodies Market Trends & Drivers
1.3.1 Arthritis Monoclonal Antibodies Industry Trends
1.3.2 Arthritis Monoclonal Antibodies Market Drivers & Opportunity
1.3.3 Arthritis Monoclonal Antibodies Market Challenges
1.3.4 Arthritis Monoclonal Antibodies Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Arthritis Monoclonal Antibodies Players Revenue Ranking (2023)
2.2 Global Arthritis Monoclonal Antibodies Revenue by Company (2019-2024)
2.3 Key Companies Arthritis Monoclonal Antibodies Manufacturing Base Distribution and Headquarters
2.4 Key Companies Arthritis Monoclonal Antibodies Product Offered
2.5 Key Companies Time to Begin Mass Production of Arthritis Monoclonal Antibodies
2.6 Arthritis Monoclonal Antibodies Market Competitive Analysis
2.6.1 Arthritis Monoclonal Antibodies Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Arthritis Monoclonal Antibodies Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Arthritis Monoclonal Antibodies as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Remicade
3.1.2 Humira
3.1.3 Enbrel
3.1.4 Rituxan
3.1.5 Orencia
3.1.6 Actemra
3.1.7 Simponi
3.1.8 Cimzia
3.2 Global Arthritis Monoclonal Antibodies Sales Value by Type
3.2.1 Global Arthritis Monoclonal Antibodies Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Arthritis Monoclonal Antibodies Sales Value, by Type (2019-2030)
3.2.3 Global Arthritis Monoclonal Antibodies Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Osteoarthritis
4.1.3 Psoriatic Arthritis
4.1.4 Ankylosing Spondylitis
4.1.5 Fibromyalgia
4.1.6 Others
4.2 Global Arthritis Monoclonal Antibodies Sales Value by Application
4.2.1 Global Arthritis Monoclonal Antibodies Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Arthritis Monoclonal Antibodies Sales Value, by Application (2019-2030)
4.2.3 Global Arthritis Monoclonal Antibodies Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Arthritis Monoclonal Antibodies Sales Value by Region
5.1.1 Global Arthritis Monoclonal Antibodies Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Arthritis Monoclonal Antibodies Sales Value by Region (2019-2024)
5.1.3 Global Arthritis Monoclonal Antibodies Sales Value by Region (2025-2030)
5.1.4 Global Arthritis Monoclonal Antibodies Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Arthritis Monoclonal Antibodies Sales Value, 2019-2030
5.2.2 North America Arthritis Monoclonal Antibodies Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Arthritis Monoclonal Antibodies Sales Value, 2019-2030
5.3.2 Europe Arthritis Monoclonal Antibodies Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Arthritis Monoclonal Antibodies Sales Value, 2019-2030
5.4.2 Asia Pacific Arthritis Monoclonal Antibodies Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Arthritis Monoclonal Antibodies Sales Value, 2019-2030
5.5.2 South America Arthritis Monoclonal Antibodies Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Arthritis Monoclonal Antibodies Sales Value, 2019-2030
5.6.2 Middle East & Africa Arthritis Monoclonal Antibodies Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Arthritis Monoclonal Antibodies Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Arthritis Monoclonal Antibodies Sales Value
6.3 United States
6.3.1 United States Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.3.2 United States Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.4.2 Europe Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.5.2 China Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.5.3 China Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.6.2 Japan Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.7.2 South Korea Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.8.2 Southeast Asia Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Arthritis Monoclonal Antibodies Sales Value, 2019-2030
6.9.2 India Arthritis Monoclonal Antibodies Sales Value by Type (%), 2023 VS 2030
6.9.3 India Arthritis Monoclonal Antibodies Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 AbbVie Inc
7.1.1 AbbVie Inc Profile
7.1.2 AbbVie Inc Main Business
7.1.3 AbbVie Inc Arthritis Monoclonal Antibodies Products, Services and Solutions
7.1.4 AbbVie Inc Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.1.5 AbbVie Inc Recent Developments
7.2 F. Hoffmann-La Roche Ltd
7.2.1 F. Hoffmann-La Roche Ltd Profile
7.2.2 F. Hoffmann-La Roche Ltd Main Business
7.2.3 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Products, Services and Solutions
7.2.4 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.2.5 F. Hoffmann-La Roche Ltd Recent Developments
7.3 Novartis
7.3.1 Novartis Profile
7.3.2 Novartis Main Business
7.3.3 Novartis Arthritis Monoclonal Antibodies Products, Services and Solutions
7.3.4 Novartis Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.3.5 Johnson & Johnson(Janssen) Recent Developments
7.4 Johnson & Johnson(Janssen)
7.4.1 Johnson & Johnson(Janssen) Profile
7.4.2 Johnson & Johnson(Janssen) Main Business
7.4.3 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Products, Services and Solutions
7.4.4 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.4.5 Johnson & Johnson(Janssen) Recent Developments
7.5 Pfizer Inc
7.5.1 Pfizer Inc Profile
7.5.2 Pfizer Inc Main Business
7.5.3 Pfizer Inc Arthritis Monoclonal Antibodies Products, Services and Solutions
7.5.4 Pfizer Inc Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.5.5 Pfizer Inc Recent Developments
7.6 Mylan
7.6.1 Mylan Profile
7.6.2 Mylan Main Business
7.6.3 Mylan Arthritis Monoclonal Antibodies Products, Services and Solutions
7.6.4 Mylan Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.6.5 Mylan Recent Developments
7.7 Genentech
7.7.1 Genentech Profile
7.7.2 Genentech Main Business
7.7.3 Genentech Arthritis Monoclonal Antibodies Products, Services and Solutions
7.7.4 Genentech Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.7.5 Genentech Recent Developments
7.8 GSK
7.8.1 GSK Profile
7.8.2 GSK Main Business
7.8.3 GSK Arthritis Monoclonal Antibodies Products, Services and Solutions
7.8.4 GSK Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.8.5 GSK Recent Developments
7.9 AstraZeneca PLC
7.9.1 AstraZeneca PLC Profile
7.9.2 AstraZeneca PLC Main Business
7.9.3 AstraZeneca PLC Arthritis Monoclonal Antibodies Products, Services and Solutions
7.9.4 AstraZeneca PLC Arthritis Monoclonal Antibodies Revenue (US$ Million) & (2019-2024)
7.9.5 AstraZeneca PLC Recent Developments
8 Industry Chain Analysis
8.1 Arthritis Monoclonal Antibodies Industrial Chain
8.2 Arthritis Monoclonal Antibodies Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Arthritis Monoclonal Antibodies Sales Model
8.5.2 Sales Channel
8.5.3 Arthritis Monoclonal Antibodies Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer